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Abstract
Background: To determine the relative abilities of compartment models to describe time-courses of 18F-
fluoromisonidazole (FMISO) tumor uptake in patients with advanced stage non-small cell lung cancer (NSCLC)
imaged using dynamic positron emission tomography (dPET), and study correlations between values of the blood
flow-related parameter K1 obtained from fits of the models and an independent blood flow measure obtained from
perfusion CT (pCT).
NSCLC patients had a 45-min dynamic FMISO PET/CT scan followed by two static PET/CT acquisitions at 2 and 4-h
post-injection. Perfusion CT scanning was then performed consisting of a 45-s cine CT.
Reversible and irreversible two-, three- and four-tissue compartment models were fitted to 30 time-activity-curves
(TACs) obtained for 15 whole tumor structures in 9 patients, each imaged twice. Descriptions of the TACs provided
by the models were compared using the Akaike and Bayesian information criteria (AIC and BIC) and leave-one-out
cross-validation. The precision with which fitted model parameters estimated ground-truth uptake kinetics was
determined using statistical simulation techniques. Blood flow from pCT was correlated with K1 from PET kinetic
models in addition to FMISO uptake levels.
Results: An irreversible three-tissue compartment model provided the best description of whole tumor FMISO uptake
time-courses according to AIC, BIC, and cross-validation scores totaled across the TACs. The simulation study indicated
that this model also provided more precise estimates of FMISO uptake kinetics than other two- and three-tissue models.
The K1 values obtained from fits of the irreversible three-tissue model correlated strongly with independent blood flow
measurements obtained from pCT (Pearson r coefficient = 0.81). The correlation from the irreversible three-tissue model
(r = 0.81) was stronger than that from than K1 values obtained from fits of a two-tissue compartment model (r = 0.68), or
FMISO uptake levels in static images taken at time-points from tracer injection through to 4 h later
(maximum at 2 min, r = 0.70).
Conclusions: Time-courses of whole tumor FMISO uptake by advanced stage NSCLC are described best by an
irreversible three-tissue compartment model. The K1 values obtained from fits of the irreversible three-tissue
model correlated strongly with independent blood flow measurements obtained from perfusion CT (r = 0.81).
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Background
The radiotracer 18F-fluoromisonidazole (FMISO) diffuses
passively into cells, where it is reduced and irreversibly
bound in hypoxic environments. Thus, positron emis-
sion tomography (PET) imaging of FMISO uptake can
be used to localize hypoxic tumor subvolumes [1–3].
The degree of hypoxia can be estimated either from up-
take levels seen in single FMISO images collected 2–4 h
after tracer injection [4], or from analysis of the kinetics
of FMISO uptake in dynamic sequences of PET images
(dPET). The kinetic analysis provides fitted values of
model rate-constants related to blood flow and FMISO
transport and intracellular binding and can be per-
formed at the whole tumor level or voxel-by-voxel. For
head-and-neck cancers, it has generated indices that cor-
relate with radiotherapy (RT) outcomes [5].
Blood flow is often imaged using a perfusion CT
(pCT) technique first proposed in 1980, in which iodine
containing contrast is injected as a bolus through a ven-
ous cannula, and its passage through the patient is dy-
namically imaged and kinetically analyzed on the
assumption that iodine concentrations within tissues are
linearly proportional to changes in measured CT attenu-
ation [6]. Blood flow measures obtained from pCT have
been found to correlate with perfusion measurements
obtained from dPET imaging of 15O-water uptake [7],
which in turn were correlated with kinetics indices ob-
tained from compartment modeling of the first 2 min of
18F-fluorodeoxyglucose (FDG) dPET scans [8].
In this study, we investigate which of several compart-
ment models best describes PET-imaged time-courses of
FMISO uptake in whole NSCLC tumors, and we identify
the model whose fits to the time-course data provide the
most precise estimates of tracer kinetics rate-constants
according to statistical simulations. Correlations are de-
termined between perfusion measures obtained directly
from the PET FMISO kinetics model fits and independ-
ently from pCT.
Methods
PET and pCT image acquisition and processing
In a pre-clinical study, the investigational drug buparlisib
(Novartis) reduced tumor hypoxia in vivo [9]. A clinical
trial (BKM120) completed in Oxford (NCT02128724)
has the primary aim of determining the maximum toler-
ated dose of buparlisib in non-small cell lung cancer
(NSCLC) patients treated palliatively using radiotherapy,
and the secondary goal of validating the pre-clinical re-
sults in these patients, who are imaged using FMISO
PET at baseline and 7 days after administration of bupar-
lisib without any other intervention. The study has been
approved by the local ethics committee and signed in-
formed consent obtained from all patients.
Patients were imaged supine with their arms by their side
using a GE Discovery 690 PET/CT scanner (GE Healthcare).
They were injected with 370 MBq FMISO 30 s into PET im-
aging, which continued for 45 min and resumed for 10 min
intervals at 2 and 4-h post-injection. Prior to each PETacqui-
sition, a CT scan was performed for localization and PET
attenuation correction. PET images were reconstructed using
a time-of-flight ordered subset expectation maximization
algorithm (VPFX, GE Healthcare). The first 45 min of data
were binned into two parallel time sequences, S1 (1 s × 30 s,
12 s × 5 s, 6 s × 10 s, 5 s × 30 s, 10 s × 60 s, 6 s × 300 s) and
S2 (1 s × 30 s, 60 s × 1 s, 12 s × 10 s, 3 s × 30 s, 10 s × 60 s,
6 s × 300 s), and reconstructed as images on a matrix of
5.5 mm3× 5.5 mm3× 3.3 mm3 voxels. Data collected during
the two later 10-min intervals were processed as single
frames [10].
pCT scanning was performed immediately after PET/
CT imaging concluded at 4-h post-injection of FMISO,
with patients set up in the same position on the same
PET/CT scanner. Initially a pre-contrast CT scan (helical
mode, 120 kV, smart mA, 32 noise index) was carried
out to determine the region over which the pCT data
would be collected. Then pCT scanning commenced
(120 kV, 60 mA), collecting one 3D image in each of 45
consecutive seconds, over an axial length of 40 mm cor-
responding to the CT detector width. During pCT scan-
ning 70 mL contrast (Omnipaque 300) was injected at
5 mL/s, followed by 25 mL water at 5 mL/s, with pa-
tients instructed to hold their breath at inspiration for as
long as possible, breathing out very slowly if necessary.
For each patient, the primary tumor, involved nodes, and
metastases were outlined on the PET/CT images by an expe-
rienced radiologist, and a blood region was defined within
the central part of the descending aorta on five or more con-
secutive PETaxial slices [11]. These were outlined on the CT
images with the patient’s prior contrast-enhanced CT
imaging used to assist in determining tumor regions.
Time-activity curves (TACs) representing time-courses of
mean FMISO tracer activity concentrations within each
tumor volume-of-interest (VOI) and the blood region were
obtained from PET sequences S1 and S2 respectively. Activ-
ity data from the 10-min frames collected at 2 and 4 h
post-injection were appended to the TACs. A total of 30
whole-volume tumor FMISO uptake TACs, obtained for 15
volumes-of-interest (9 primary tumors, 5 involved nodes,
and 1 metastasis) in 9 patients, each imaged twice were stud-
ied (Table 1). Using a standard tumor to blood ratio of 1.4
(on the static images four hours post-injection), all of these
whole tumor volumes had a number of voxels within them
which could be considered to be hypoxic [4]. No direct oxy-
gen measurements of the tumors were made in this trial.
Using Hermes Hybrid Viewer software (Hermes Medical
Solutions AB, Sweden), the CT images obtained at PET/CT
were rigidly registered with the CT images collected just
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before pCT, allowing outlines of the primary tumors de-
fined on the PET/CT to be transferred to the pCT scans.
An example of a FMISO PET/CT image 4 h post-injection
is shown in Fig. 1.
PET kinetics analysis and model fitting
Several methods have been used to analyze dPET data, the
most common being compartment modeling [12]. Figure 2
illustrates reversible two-, three-, and four-tissue linear
compartment models which we have fitted to time-courses
of tumor tracer uptake [13–15]. FMISO binding is generally
considered irreversible, and therefore, alongside reversible
models, we have also studied irreversible models in which
the rate-constant describing movement of bound to
unbound tracer is set to zero. The compartment model
developed by Casciari et al. [2] attempts to reflect the
chemical processes that occur for FMISO uptake; however,
this model has many fitting parameters, and so in this
work, simpler compartment models have been investigated.
We denote by xCyK a model comprising a linear chain of
x-tissue compartments (excluding blood-borne tracer) and
y rate-constants, and in order to associate rate-constants
with particular models, we add the subscript xC to the
names of rate-constants, except for those of the
three-tissue compartment model.
Kinetics analysis was carried out using the PMOD sys-
tem (PMOD Technologies) as described by McGowan et
al. [10] In brief, an image-derived FMISO input function
[16, 17] was obtained from the blood region outlined
within the descending aorta, and a compartment model
was fitted to the tumor TAC and input function data,
generating fitted values of model rate-constants. Fitting
was carried out by minimizing the weighted sum of
squares between modeled and measured tumor uptake,
using the Levenberg–Marquardt algorithm with weight-
ing function
wi ¼ Δti exp −λtið Þ=CPET tið Þ ð1Þ
where ti and Δti are the mid-time post-injection and
duration of the ith of T frames, λ is the decay constant
for 18F, and CPET the measured PET activity concentra-
tion at time ti [15, 17].
Model fitting was initiated from 100 randomly generated
sets of starting values (suitably constrained), to attempt to
reach global rather than local best fits [18]. Flux-constants
were calculated from irreversible two-tissue compartment
model (2C3K) fits as
kflux−2C ¼ K1−2C k3−2Ck2−2C þ k3−2C ð2Þ
and from irreversible three-tissue (3C5K) compartment
model fits as
kflux ¼ K 1k3k5k2k4 þ k2k5 þ k3k5 ð3Þ
Assessment of PET kinetic model fits
The Wald–Wolfowitz runs-test was used to determine the
adequacy of descriptions of FMISO uptake TACs provided
by compartment model fits [19, 20]. To further assess the
relative abilities of the different models to describe the data,
we used the Akaike information criterion (AIC) [21] cor-
rected for small sample size [22], the Bayesian information
criterion (BIC) [22], and leave-one-out cross-validation [23].
The cross-validation approach proceeded by fitting each
model to the complete dataset minus one point, calculating
the differences between the value of the omitted data-point
and values predicted by the models, repeating this process
sequentially T times leaving out a different data-point each
time, and finally calculating the mean of the squared error
of prediction (MSEP) for each model, the model with the
lowest MSEP being considered best. These model selection
methods use slightly different criteria to determine the
model that best describes the data (all penalizing highly
Table 1 Details of the 30 whole tumor TACs analyzed
Patient VOIs and TAC reference numbers in images taken pre/post
drug administration
1 Primary (1/2)
2 Primary (3/4), metastasis (5/6)
3 Primary (7/8)
4 Primary (9/10)
5 Primary (11/12)
6 Primary (13/14), node (15/16)
7 Primary (17/18), node (19/20)
8 Primary (21/22), node 1 (23/24), node 2 (25/26), node 3 (27/28)
9 Primary (29/30)
Fig. 1 An example coronal FMISO PET image fused with the
corresponding CT displayed on a tumor to blood ratio (TBR) color
scale. Red regions depict a TBR > 1.4 indicating hypoxia, and no
visible PET depicts a TBR < 1, indicating normoxia [4]
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parameterised models which are likely to over fit the data),
for completeness all have been included in this work.
A statistical simulation procedure was used to assess
which model produced the most accurate and precise
rate-constant estimates [10]. For this analysis, we used
3C5K and 3C6K model fits to the 30 measured whole
tumor TACs to create noise-free “ground-truth” TACs
binned into the same frame-lengths as the original data,
and the parameter values of these fits were taken as
ground-truth rate-constants. For each of the resulting 60
ground-truth TACs, 1000 noisy TACs were simulated by
adding normally distributed random variables to the
activity concentrations of the individual time-frames, the
variances of the noise differing between frames accord-
ing to the inverse of Eq. (1) and scaled to match
noise-levels seen on the measured whole tumor TACs
[10, 15, 24–26]. The average whole tumor scaling factor
with the weighting factor used here was 0.6 ± 0.3 (one
standard deviation). The simulated TACs were then
fitted using the 2C3K, 2C4K, 3C5K, and 3C6K models.
The simulated noise introduces random uncertainties
and systematic error (bias) into fitted parameter values,
adding to any underlying bias that results from mis-
matches between the fitted models and the ground-truth
models used to generate the simulated TACs. As de-
scribed by McGowan et al. [10], for each of the 30
ground-truth TACs associated with each ground-truth
model, individual biases in parameter values were deter-
mined from fits to the 1000 noise realizations, and then
these bias estimates were combined to calculate the
overall mean bias (MB) and variance of bias values (σ2B )
across the ground-truth TACs. The mean variance (σ2P )
was calculated for each parameter as the average of the
parameter variances obtained for each of the 30
ground-truth TACs. Then, the σB and σP terms were
combined to generate a total uncertainty, σT, given by
σT ¼ σ2B þ σ2P
 1=2 ð4Þ
For some fitted models, certain individual rate-constants
are not uniquely related to any single ground-truth model
parameter: for example, the processes described by the K1–2C
parameter of two-compartment models are split between
rate-constants K1 and k3 in three-compartment models. For
such rate-constants, therefore, only the σP values were
calculated.
Perfusion CT analysis and comparison with PET kinetic
modeling
The small size of pCT image voxels (0.7 mm ×
0.7 mm × 50 mm) makes parametric images of perfusion
susceptible to movement [27], which can easily occur as it is
difficult for patients to hold their breath for the full duration
of pCT scanning. We therefore used a non-rigid image
A
B
C
Fig. 2 a Two-, b three-, and c four-tissue compartment models used to analyze the dynamic PET data. Flow rates from one compartment to another
are defined by rate-constants (k values), tracer concentrations and compartment volumes [12]. The fraction of the tumor volume occupied by blood is
denoted in each model as νB
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registration algorithm to pre-process the pCT data. The
algorithm was based on the diffeomorphic demons ap-
proach, modified by use of normalized gradient fields
(NGF) to handle intensity changes caused by contrast up-
take. The registration algorithm uses a multi-resolution
framework with three levels (128 × 128 × 8, 256 × 256 × 8,
512 × 512 × 8), the final spacing being equal to the original
voxel spacing. The maximum number of iterations for
each level was 25, and the standard deviation of the
Gaussian smoothing kernel was 2.8 mm, 1.4 mm, and
0.7 mm at the different resolution levels. Further details
have been provided by Papiez et al [27].
The motion-corrected pCT data was then processed
voxel-by-voxel using the commercial GE Perfusion 4D soft-
ware (GE Healthcare, Milwaukee, USA). Voxel-by-voxel
tumor blood flow information was obtained by fitting the
Adiabatic Approximation to the Tissue Homogeneity
(AATH) model [28] to the pCT TACs of each voxel, which
describe the variation of voxel X-ray attenuation coefficient
with time. Similarly to the compartment models used in the
PET kinetics analysis, the AATH model describes the
time-course of attenuation, and thus of iodine uptake, as the
convolution of an iodine input function, obtained from a
VOI drawn in the center of the descending aorta, with a resi-
due function containing fittable parameters. A schematic of
the AATH model is shown in Fig. 3: unlike the PET models,
blood flowing through the tumor is considered to have a fi-
nite transit time, with contrast exchanged between intra and
extravascular spaces only at the venous outlet.
Voxel-by-voxel values of blood flow, BF, were taken
from the resulting parametric images and averaged over
tumor volumes. Then, the averaged BF values for each
tumor volume were compared to measures obtained
from PET kinetics analysis. When the whole tumor vol-
ume exceeded the 4-cm axial length of the pCT scans, as
shown in Fig. 4, the PET kinetic analysis was repeated
just for the tumor subvolume lying within the pCT field
of view, allowing results obtained from pCT perfusion
and PET kinetics analyses to be meaningfully compared.
The K1 rate-constant obtained from PET kinetic modeling
is conceptually linked to BF via
K1 ¼ BF  E ð5Þ
in which the extraction fraction E for a cylindrical capil-
lary is given by [29, 30]
E ¼ 1− exp −PS=BFð Þ ð6Þ
where P is capillary permeability, S the surface area per
unit volume, and PS the permeability surface area prod-
uct. For highly permeable tracers such as FMISO [31],
PS is much greater than BF and the extraction fraction
is close to 1. Consequently, BF measurements obtained
from pCT scans should be approximately equal to K1
derived from FMISO PET kinetic modeling. We have
therefore determined the Pearson r coefficients of correl-
ation between pCT tumor mean BF values and K1 values
obtained from 2C3K and 3C5K compartment model fits
to the dPET data. Correlations were also evaluated
between BF values and static FMISO uptakes at each
time-point in the dynamic series of images, and between
BF and the average FMISO uptakes over the first 2 min
post-injection.
Results
Quality of compartment model fits to FMISO TACs
The numbers of whole tumor FMISO TACs for which
fits of each compartment model passed the runs-test are
listed in Table 2, together with total AIC, BIC, and
MSEP scores for the different models summed over all
TACs, and the numbers of TACs for which each model
achieved the lowest scores. Runs-test results are pre-
sented individually for each whole tumor TAC in
Additional file 1: Table S1 with corresponding AIC, BIC,
and MSEP scores detailed in Additional file 2: Table S2.
The three- and four-tissue models passed the runs-test
for 83–100% of whole tumor TACs, whereas two-tissue
model fits passed for only 0–20% [32]. Summed AIC,
Fig. 3 Schematic of the AATH model used to analyze the perfusion CT
data: BF is the blood flow through the tumor, vP the intravascular
plasma volume fraction, ve the extracellular extravascular space, and PS
the permeability surface area product which defines the exchange rate
between plasma and the extravascular extracellular space
Fig. 4 A coronal slice taken from one patient; the section in color
indicates the volume over which the pCT was performed, while the
underlying greyscale CT is from the pre-contrast CT
McGowan et al. EJNMMI Research  (2018) 8:73 Page 5 of 10
BIC, and MSEP scores were much lower for three- and
four-tissue models than for two-tissue models, which
lacked the flexibility to describe the data well. Fits of the
2C3K, 2C4K, and 3C5K models to two example TACs
(4 and 24) are plotted in Fig. 5.
The irreversible three-tissue model, 3C5K, achieved
the lowest AIC, BIC, and MSEP scores totaled over all
tumor TACs, and the lowest scores for most (21–24)
individual TACs. Individual scores were generally a little
higher for the 3C6K, 4C7K, and 4C8K models, their
additional complexity usually being unnecessary to
describe the TAC data.
Table 3 lists estimates of parameter accuracy and pre-
cision obtained from the statistical simulations, which
used fits of the 3C5K and 3C6K models to measured
FMISO TACs to represent the ground-truth, the 3C5K
model offering the best description of the TACs accord-
ing to the AIC, BIC, and MSEP measures. Parameter
values obtained from fits of the 2C4K model to simu-
lated noisy TACs had large mean biases and total uncer-
tainties, irrespective of which three-tissue ground-truth
model was used. Mean biases and uncertainties of fitted
2C3K model parameters were not so large as for 2C4K,
but were still considerably larger than those estimated
for three-compartment models.
For parameters νB, K1, k2, k3, and k4, mean biases and
total uncertainties were similar for 3C5K and 3C6K
model fits, regardless of which three-tissue model was
Table 2 Summary of runs-test results and totaled AIC, BIC, and
MSEP scores for compartment model fits to all 30 whole tumor
FMISO TACs. Lowest totaled AIC, BIC, and MSEP scores are
underlined, indicating the best model according to those measures
Model 2C3K 2C4K 3C5K 3C6K 4C7K 4C8K
Runs-test passes from fits to all 30 TACs
Runs 0 6 25 26 30 30
Information criteria and cross-validation scores summed for all TACs
AIC 13,970 8600 1544 1554 1557 1644
BIC 14,174 8836 1813 1840 1850 1945
MSEP 219 131 24.6 26.9 24.8 27.9
Numbers of TACs for which each model has the lowest scores
AIC 0 0 21 3 6 0
BIC 0 0 22 3 5 0
MSEP 0 0 24 3 3 0
Fig. 5 Fits of the 2C3K, 2C4K, and 3C5K models to FMISO TACs 4 (plots a and c) and 24 (b and d). Time post-injection is plotted on linear (a/b)
and logarithmic (c/d) scales to enable the early part of the TAC and modeled TAC to be visualized
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used to represent the ground-truth. For the k5 and kflux
parameters, however, mean biases and total uncertainties
were notably lower for 3C5K than for 3C6K model fits
when the ground-truth was represented by the 3C5K
model. Total uncertainties on 3C5K fits remained less
than those on 3C6K fits even when the 3C6K model was
used to represent the ground-truth, although in this
circumstance 3C5K fit parameters had slightly higher
mean biases than 3C6K fits.
Overall, the 3C5K model provided the most precise
estimates of FMISO uptake kinetics according to statis-
tical simulations, and the model’s accuracy was only
surpassed by 3C6K when this reversible model was also
considered to represent the ground-truth, despite the
known irreversibility of FMISO binding.
Correlations between K1 and BF parameters obtained
from FMISO dPET and pCT
Tumor K1 values obtained from fits of the 3C5K and 2C3K
models to the FMISO dPET data are plotted in Fig. 6
against BF values independently obtained from pCT ana-
lysis. The 3C5K-based K1 values were strongly correlated
with BF (Pearson r coefficient = 0.81), whereas 2C3K-based
K1 values were less strongly correlated (r = 0.68). Pearson r
coefficients of correlation between BF and static FMISO
tumor uptake in frames collected at different times are
plotted in Fig. 7, the maximum correlation (r = 0.70) being
obtained at 2-min post-injection.
Discussion
Whole tumor FMISO TACs obtained from dPET scans of
advanced stage NSCLC patients were described better by
an irreversible three-tissue compartment model, 3C5K,
than by other compartment models we studied, according
to information criterion and cross-validation scores, and
statistical simulations. Total information criterion and
cross-validation scores were much worse for simpler
two-tissue compartment models and slightly worse for the
reversible three-tissue model, 3C6K, and for four-tissue
models whose additional complexity was unnecessary. In
statistical simulation studies, total uncertainties calculated
for fitted 3C5K model parameter values were consistently
lower than those found for two-tissue compartment
model fits, and a little lower than for 3C6K fits, even when
the 3C6K model was used to represent the ground-truth.
For five of the measured whole tumor TACs, the
3C5K model fits did not pass a runs-test whereas the
four-tissue compartment model fits did. For these par-
ticular TACs, we therefore carried out further statistical
simulations, using 3C5K and 4C7K models as
ground-truth. Even for these specific cases, fits of the
3C5K model provided more precise estimates of
ground-truth kinetics values than did 4C7K fits, regard-
less of the ground-truth model used in the simulations.
Table 3 Estimates of the accuracy and precision of parameter
values obtained from fits of the 2C3K, 2C4K, 3C5K, and 3C6K
models to whole tumor TACs simulated by adding whole
tumor-level noise to the ground-truth, represented as 3C5K and
3C6K model fits to real TACs. Values of MB, σB, σP, and σT are
shown for fitted parameters as percentages of the mean values
of directly related ground-truth parameters in the 3C5K or 3C6K
models. When no directly related parameter exists, σP is listed
alone as a percentage of the mean fitted parameter value
Model fitted Fitted model parameters
Ground-truth 3C5K model
2C3K vB–2C K1–2C k2–2C k3–2C kflux–2C
MB (%) 47 – – −40 25
σB (%) 24 – – 23 11
σP (%) 14 30 36 12 13
σT (%) 27 – – 26 17
2C4K vB–2C K1–2C k2–2C k3–2C k4–2C kflux–2C
MB (%) 25 – – 565 – 1014
σB (%) 20 – – 700 – 1049
σP (%) 9 7 13 73 45 47
σT (%) 22 – – 704 – 1050
3C5K vB K1 k2 k3 k4 k5 kflux
MB (%) 0 − 1 0 1 0 0 0
σB (%) 4 1 2 4 3 1 0
σP (%) 10 5 10 20 11 10 6
σT (%) 10 5 10 20 12 10 6
3C6K vB K1 k2 k3 k4 k5 k6 kflux
MB (%) 0 0 1 5 3 13 – 13
σB (%) 4 1 2 7 5 17 – 16
σP (%) 10 5 9 22 13 34 384 31
σT (%) 11 5 9 23 14 38 – 35
Ground-truth 3C6K model
2C3K vB–2C K1–2C k2–2C k3–2C kflux–2C
MB (%) 48 – – − 51 4
σB (%) 24 – – 49 33
σP (%) 13 36 42 11 10
σT (%) 27 – – 50 35
2C4K vB–2C K1–2C k2–2C k3–2C k4–2C kflux–2C
MB (%) 25 – – 510 3173 914
σB (%) 20 – – 748 3768 1122
σP (%) 11 16 36 65 44 40
σT (%) 23 – – 751 3768 1123
3C5K vB K1 k2 k3 k4 k5 kflux
MB (%) 0 − 1 − 2 − 5 − 5 − 18 − 11
σB (%) 3 1 2 7 5 21 18
σP (%) 10 5 10 21 11 10 8
σT (%) 10 5 10 22 12 23 19
3C6K vB K1 k2 k3 k4 k5 k6 kflux
MB (%) − 1 0 1 4 3 8 86 6
σB (%) 3 1 2 5 4 9 131 8
σP (%) 10 5 9 21 13 27 164 22
σT (%) 10 5 9 21 13 29 210 24
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A strong correlation (r = 0.81) was found between the
K1 parameter values of the 3C5K model fits to the
FMISO TACs and BF values independently obtained
from pCT. The K1 values obtained from 2C3K model fits
correlated less strongly (albeit not significantly less
strongly) with BF (r = 0.68), lending weight to the results
indicating that the 3C5K model describes whole tumor
FMISO kinetics better than 2C3K. The K1 values
obtained from 3C5K model fits were also more strongly
correlated with BF than were whole tumor FMISO
A
B
Fig. 6 K1 values obtained from (a) 3C5K and (b) 2C3K compartment model fits to FMISO dPET data, plotted against BF values determined from pCT scans
Fig. 7 Pearson r coefficients of correlation between BF values and FMISO uptake at a range of times post-injection
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uptake values at times ranging from tracer injection to
4 h later (maximum correlation r = 0.70).
FMISO dPET imaging is used to measure hypoxia, and
since hypoxia is related to perfusion, pCT perfusion
scans are sometimes collected as well. Since BF is
strongly correlated with the K1 values obtained from
3C5K model fits to FMISO dPET data, blood flow could
potentially be estimated directly from the K1 values ob-
tained from the FMISO images, rather than from pCT,
thus saving time, money and the pCT radiation dose,
and generating BF data over the 15 cm axial width of
modern PET scanner fields-of-view, rather than 4-cm
axial width typical of CT scanners used in cine-mode.
Blood flow could also be estimated from FDG dPET data
if available (not a hypoxia tracer), since BF values ob-
tained from 15O-labeled water dPET studies have previ-
ously been shown to strongly correlate with parameter
values obtained from model fits to the first 2 min of
FDG dPET scans (r = 0.86) [33].
The gold-standard method for determining input func-
tions is direct arterial line sampling. However, we have
used image-derived input functions (IDIFs) calculated
from mean tracer activity concentrations within volumes
drawn in the descending aorta, both for patient comfort
and safety, and because good agreement has been dem-
onstrated between directly sampled input functions and
IDIFs obtained from the descending aorta [11].
In this study, we have assessed the performance of PET
kinetic models in terms of information criteria scores,
cross-validation measures, statistical simulations, and
strengths of correlations with an independent measure of
perfusion. The imaging protocol used in this work is de-
manding, as we are currently investigating whether shorter
protocols can provide adequate rate-constant estimates. In a
recently opened study (Atovaquone as Tumor HypOxia
Modifier, NCT02628080), surgically treated NSCLC patients
are being imaged using dynamic FMISO PET prior to tumor
excision, allowing us to compare FMISO images and para-
metric maps directly with maps of histopathology obtained
from excised tumor slices.
Conclusions
Time-courses of whole tumor FMISO uptake in patients
with advanced stage NSCLC were described better by an
irreversible three-tissue compartment model, 3C5K, than
by other two-, three-, or four-tissue compartment models
investigated. Fits of this model also provided the most pre-
cise estimates of FMISO uptake kinetics according to
simulation studies. Further evidence for the utility of the
3C5K model was provided by the observation of a strong
correlation (r = 0.81) between fitted values of its K1
parameter and blood flow values obtained independently
from perfusion CT imaging, a stronger correlation than
that between blood flow and K1 values obtained from
2C3K model fits, or between blood flow and tumor
FMISO uptake in static scans taken at a range of times
from immediately post-injection to 4 h later.
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